Novavax to Research combined influenza/Covid-19 vaccine for use post pandemic

Novavax Inc said on Tuesday it has established a group of business veterans as it attempts U.S. regulatory approval for its seasonal flu vaccine and also to help develop joint influenza/Covid-19 vaccine to be used following the pandemic.

The influenza vaccine, NanoFlu, fulfilled the secondary and primary aims in late-stage comparison research with Sanofi’s flu vaccine Fluzone Quadrivalent earlier in the year.

Novavax is one of the global drugmakers rushing to create a vaccine for Covid-19 and the final month began a late-stage trial of its experimental drug, NVX-CoV2373, in the UK.

NVX-CoV2373 is also being analyzed in two continuing mid-stage trials which started in August.